Introduction {#Sec1}
============

Post-transplant diabetes mellitus represents a major adverse effect of immunosuppressive drugs^[@CR1]--[@CR4]^ and is associated with high cumulative incidence of cardiac events, vascular disease, and overall impaired survival rates^[@CR5]^. Sirolimus (rapamycin) was introduced in the Edmonton immunosuppression protocol in islet transplant recipients^[@CR6],[@CR7]^, attempting to minimize the diabetogenic effects observed with corticosteroids and other immunosuppressive regimens. Despite the initial enthusiasm, 5-year results of this clinical trial revealed that only \~10% of patients maintained insulin independence^[@CR1],[@CR8]^, endorsing the detrimental role of sirolimus in glucose homeostasis.

A randomized trial of immunosuppressive drugs in kidney transplantation, the Efficacy Limiting Toxicity Elimination (ELITE) -- Symphony study^[@CR9]^, identified sirolimus as the one with the highest incidence of hyperglycemia, even higher than calcineurin inhibitors^[@CR9]^. Since then, several investigators sought to determine the mechanisms underlying new-onset diabetes mellitus after transplantation^[@CR10]--[@CR13]^. The effects of sirolimus *in vivo* are quite complex, as confirmed by numerous controversial findings: indeed, albeit several studies demonstrate that its administration causes glucose intolerance^[@CR14]--[@CR16]^, there are also reports showing that it does improve insulin sensitivity in diabetic mice^[@CR17]^, protects against obesity^[@CR18],[@CR19]^, reduces atherosclerosis^[@CR20],[@CR21]^ and cardiac or renal fibrosis^[@CR22],[@CR23]^, and extends lifespan^[@CR24]^.

We decided to test the effects of sirolimus in pancreatic β cells. Our hypothesis is that one of the mechanisms underlying the diabetogenic action of sirolimus is the impairment of metabolism-secretion coupling in β cells. We focused on the effect of sirolimus on the key organelle in metabolism-secretion coupling, *i.e*. the mitochondrion^[@CR25]--[@CR28]^. Indeed, such organelle is considered the main responsible for coupling different fuel secretagogues to insulin exocytosis, through a process that includes oxidation of nutrients within the mitochondrial matrix and subsequent ATP generation, increasing intracellular calcium (Ca^2+^) via closure of ATP-sensitive K^+^ channels and depolarization of the plasma membrane^[@CR27]--[@CR32]^.

Results {#Sec2}
=======

Sirolimus impairs glucose-induced insulin secretion in pancreatic β cells {#Sec3}
-------------------------------------------------------------------------

To test the effect of sirolimus on pancreatic β cell function, we evaluated the response to glucose in INS-1 β cells. We first performed a dose-response assay, and we found that increasing doses of sirolimus progressively reduce glucose-stimulated insulin secretion (GSIS, Fig. [1a](#Fig1){ref-type="fig"}). Then, we performed a time-course experiment using the dose of sirolimus (25 nM) that has been measured in the blood of transplant recipients^[@CR33]^ and we observed that a 24-hour incubation significantly decreased GSIS (Fig. [1b](#Fig1){ref-type="fig"}). Importantly, we did not detect any significant effect of sirolimus on cell viability (Fig. [1c](#Fig1){ref-type="fig"}). These results were also confirmed in murine (Fig. [1d,e](#Fig1){ref-type="fig"}) and in human (Fig. [1f,g](#Fig1){ref-type="fig"}) islets.Figure 1Sirolimus impairs glucose-stimulated insulin secretion from pancreatic β cells. Evaluation of the effect of sirolimus on clonal rat β cells (**a**--**c**), murine islets (**d**,**e**) and human islets (**f**,**g**). INS-1 β cells were treated for 24 h with vehicle or sirolimus at the indicated doses (**a**). INS-1 β cells were treated with vehicle or sirolimus (25 nM) for the indicated times (**b**). INS-1 β cells were treated for 24 h with 25 nM sirolimus (**c**). Effect of 25 nM sirolimus (24 h) on insulin release and cell viability in murine (**d**,**e**) and human islets (**f**,**g**). Data are presented as mean ± s.e.m of at least 5 experiments (clonal β cells and murine islets) or at least 3 experiments (human islets) performed in triplicate. \*p \< 0.05 *vs* vehicle. In panel c, data are expressed as percentage of the responses determined following treatment with vehicle, taken as 100%.

Sirolimus reduces mitochondrial respiration in pancreatic β cells {#Sec4}
-----------------------------------------------------------------

When testing the effect of sirolimus on insulin release in response to the fuel secretagogues leucine and glutamine, which are known to stimulate insulin exocytosis through increased mitochondrial metabolism^[@CR34]^, we found a significantly impaired response in sirolimus-treated cells (Fig. [2a](#Fig2){ref-type="fig"}), whereas cells from both groups were similarly responsive to KCl-mediated depolarization (Fig. [2b](#Fig2){ref-type="fig"}). We obtained similar findings in murine (Fig. [2c,d](#Fig2){ref-type="fig"}) and in human (Fig. [1e,f](#Fig1){ref-type="fig"}) islets, thereby suggesting an action of the immunosuppressant drug on the mechanisms underlying metabolism-secretion coupling. Therefore, we tested the effect of sirolimus on mitochondrial respiration, observing a significant decrease in oxygen consumption rate (OCR) in clonal β cells (Fig. [3](#Fig3){ref-type="fig"}) and in islets isolated from mice and humans (Figure [S1](#MOESM1){ref-type="media"}) treated with sirolimus.Figure 2Sirolimus compromises insulin secretion from β cells in response to fuel secretagogues. INS-1 β cells (**a**,**b**), murine islets (**c**,**d**) and human islets (**e**,**f**) were incubated for 24 h with vehicle or 25 nM sirolimus and then stimulated with leucine (Leu) and glutamine (Gln, panels **a**,**c**,**e**) or with KCl (panels **b**,**d**,**f**). Data are presented as mean ± s.e.m of at least 3 experiments performed in triplicate. \*p \< 0.05 *vs* vehicle. Figure 3Sirolimus impairs mitochondrial respiration in pancreatic β cells. The time course of oxygen consumption rate (OCR) was measured using the Extracellular Flux Analyzer in β cells incubated for 24 h with vehicle or 25 nM sirolimus and then treated with glucose, oligomycin, phenylhydrazone (FCCP), antimycin A and rotenone (panel **a**); see methods for further details. The maximal respiratory capacity is quantified in panel **b**, in which whiskers represent 5% to 95% spread of the data. Data represent mean ± s.e.m. of 4 independent experiments, each performed in at least 7 replicates. \*p \< 0.05 *vs* vehicle.

Sirolimus decreases mitochondrial Ca^2+^ uptake in β cells {#Sec5}
----------------------------------------------------------

Mounting evidence indicates that Ca^2+^ represents a major regulator of mitochondrial function, and a decreased uptake of this ion by this organelle has been functionally linked to reduced mitochondrial respiration in various cell types^[@CR35]--[@CR39]^. Thus, we assessed mitochondrial Ca^2+^ uptake in pancreatic β cells following incubation with sirolimus and we observed a significantly decreased uptake compared with vehicle-treated cells (Fig. [4a,b](#Fig4){ref-type="fig"}). We and others have demonstrated the importance of ER Ca^2+^ in β cell function^[@CR31],[@CR40]--[@CR45]^. Since sirolimus has been reported to modulate intracellular Ca^2+^ fluxes in different tissues^[@CR46]--[@CR49]^, we assessed ER Ca^2+^ stores and we found that sirolimus-treated β cells exhibited depleted intracellular Ca^2+^ stores and increased Ca^2+^ leak (Fig. [4c,d](#Fig4){ref-type="fig"}). When measuring cytosolic Ca^2+^ levels, we also observed a slightly reduced response to glucose in sirolimus-treated β cells (Figure [S2](#MOESM1){ref-type="media"}), further supporting our data on decreased GSIS.Figure 4Effects of sirolimus on Ca^2+^ dynamics in mitochondria and endoplasmic reticulum (ER). Mitochondrial Ca^2+^ uptake was measured in clonal β cells incubated for 24 h with vehicle or 25 nM sirolimus and then stimulated with glucose (16.7 mM, panel **a**). Amplitude of mitochondrial response was calculated as the level of Rhod-2 *F*1/*F* ~0~ at the peak (**b**). ER Ca^2+^ stores (**c**) and ER Ca^2+^ leak (**d**) were assessed following 24 h incubation with vehicle or 25 nM sirolimus. In panel c, the green arrowhead indicates thapsigargin (1 μm). Data are presented as mean ± s.e.m of at least 4 experiments performed in triplicate. \*p \< 0.05 *vs* vehicle. In panel b, whiskers represent 5% to 95% spread of the data.

Sirolimus regulates the expression of inositol 1,4,5-trisphosphate receptor in clonal β cells and human and murine islets {#Sec6}
-------------------------------------------------------------------------------------------------------------------------

Since sirolimus is known to modulate transcriptional activity^[@CR50]--[@CR52]^, we tested its effect on the expression levels of key players in Ca^2+^ handling, namely inositol 1,4,5-trisphosphate receptor (IP3R)^[@CR53]^, ryanodine receptor (RyR)^[@CR31],[@CR54]^ and sarco/endoplasmic reticulum Ca^2+^-ATPase (SERCA)^[@CR44]^ in clonal β cells and human and murine islets. We observed a significant upregulation of all three IP3R isoforms in sirolimus-treated compared with vehicle-treated cells, a result that was consistent in all of the tested species (rat, mouse, human, Fig. [5](#Fig5){ref-type="fig"}), strongly suggesting that the modulation of IP3R is one of the mechanisms underlying the effects of sirolimus on pancreatic β cells.Figure 5Effects of sirolimus on the expression of IP3Rs, RyR2 and SERCA in clonal β cells and murine and human islets. The effects of sirolimus (25 nM, 24 h) on mRNA levels of IP3Rs, RyR2, and SERCA in rat β cells (**a**) and murine (**b**) and human (**c**) islets were evaluated by real-time RT-qPCR analysis of total RNA, relative to vehicle-treated samples (horizontal dashed line), using GAPDH as internal standard. Primer sequences are reported in Supplementary Table [2](#MOESM1){ref-type="media"}. Each bar represents mean ± s.e.m. of at least 3 independent experiments in each of which reactions were performed in triplicate. \**P* \< 0.05 vs vehicle.

Discussion {#Sec7}
==========

Immunosuppressive therapy has been shown to be associated with glucose intolerance and post-transplantation diabetes mellitus; such a diabetogenic effect is common to immune-modulating agents acting via different mechanisms of action^[@CR3],[@CR9],[@CR55]^, including β cell failure^[@CR4],[@CR13],[@CR56],[@CR57]^ and alteration of metabolic parameters controlled by insulin signaling^[@CR58]--[@CR61]^. Here we show that sirolimus has a detrimental effect on Ca^2+^ handling and GSIS both in human and murine islets and in rat insulinoma cell line INS-1.

We also demonstrate that at 25 nM -- the dose measured in the blood of transplanted patients^[@CR33]^ -- sirolimus does not significantly affect cell vitality, consistent with previous experiments performed in various cell types revealing that only supra-therapeutic doses of sirolimus lead to increased apoptosis and reduced cell proliferation^[@CR49],[@CR56],[@CR62]^, without affecting overall insulin content^[@CR56]^. Furthermore, earlier investigations had established that immunosuppressant drugs, when used at concentrations comparable with therapeutic levels in humans, do not cause apoptosis in pancreatic β cells^[@CR63]^.

We show here for the first time that sirolimus significantly compromises mitochondrial respiration, directly assessed by measuring oxygen consumption, both in pancreatic islets and clonal β cells. The direct modulation of intracellular Ca^2+^ release channels on the ER offers a novel mechanistic insight on the diabetogenic effect of sirolimus. Intriguingly, the upregulation of IP3R observed in pancreatic β cells following sirolimus treatment is consistent with the recent observation that IP3R levels are increased in islets from diabetic patients, mirrored by a reduced number of interactions between ER and mitochondria^[@CR64]^. Additionally, Madec and colleagues had shown that exposing pancreatic islets to high glucose concentrations led to increased levels of IP3R^[@CR65]^. Also, mutations in the gene encoding for IP3R have been associated to perturbations in glucose homeostasis and enhanced susceptibility to diet-induced diabetes mellitus^[@CR66]^. Further studies are necessary to better delineate the exact role of IP3Rs in the regulation of Ca^2+^ fluxes in β cells and to identify other potential mechanisms.

Interestingly, the properties of sirolimus observed in β cells are cell-specific and seem to be in contrast with its effects seen in models of neurodegenerative and ischemic disorders^[@CR67],[@CR68]^, in which the drug has been shown to be overall protective, inducing autophagy and enhancing lysosomal activation in order to remove damaged mitochondria^[@CR69]^. The complexity of the pathways induced by sirolimus is further confirmed by the experimental findings of Fuhrer and colleagues, who observed that, despite sirolimus significantly suppresses β cell response to glucose (in agreement with our findings), the incubation of RIN-5F cells with high doses of sirolimus in absence of glucose can instead increase insulin secretion^[@CR57]^. However, opposite to their results, Barlow and colleagues found that 200 nM sirolimus caused a significant reduction in both basal and glucose-stimulated insulin release in Min-6 cells^[@CR56]^. The exact mechanisms underlying such different pharmacologic responses need to be characterized in future studies.

Materials and Methods {#Sec8}
=====================

Cells {#Sec9}
-----

Human islets with \>90% purity and viability were obtained from non-diabetic de-identified cadaveric donors through the *Integrated Islet Distribution Program* (*IIDP*). The characteristics of the donors are reported in Supplementary Table [1](#MOESM1){ref-type="media"}. Upon receipt, the islets were cultured as described^[@CR70]^. Murine islets of Langerhans were isolated as previously described^[@CR31]^. Procedures on rodents have been performed according to guidelines and regulations approved by the Einstein Animal Care and Use Committee. INS-1 cells were maintained in monolayer culture in RPMI-1640 medium, as previously described by our group^[@CR71]^. Insulin levels were determined as described and validated^[@CR31],[@CR71]--[@CR73]^. In some experiments the cells were treated with glucose (5.5 and 16.7 mM, Bio-Techne, Abingdon, UK), sirolimus (LC Laboratories, Woburn, MA, dissolved in dymethylsulfoxide), or L-leucine (10 mM, MyBioSource, San Diego, CA, USA) and glutamine (2 mM, MyBioSource). Cell viability was estimated by the \[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide, MTT colorimetric assay, spectophotometrically (570 nm) measuring the ability of metabolically active cells to reduce MTT.

Extracellular flux analyses {#Sec10}
---------------------------

Extracellular flux analyses were performed using the Extracellular Flux Analyzer (Agilent Technologies, Santa Clara, CA, USA), according to the manufacturer's instructions. Specifically, the following drugs were added to each well: glucose (16.7 mM, at minute 32) to determine response to high glucose; oligomycin (1 μM, at minute 104) to inhibit ATP synthase and assess coupling efficiency; carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP, 0.5 μM, at minute 176) to uncouple the mitochondrial oxidative phosphorylation and measure both maximum respiration and spare capacity; antimycin A and rotenone (both 1 μM, at minute 216) to inhibit the respiratory chain and measure non-mitochondrial respiration. After each assay, the cells were collected to quantify DNA via QuantiFluor dsDNA System (Promega, Madison, WI, USA), according to the manufacturer's instructions.

Ca^2+^ dynamics in cytosol, ER and mitochondria {#Sec11}
-----------------------------------------------

Ca^2+^ dynamics were evaluated as previously described and validated^[@CR74]--[@CR77]^. Briefly, cells attached on glass bottom culture dishes (MatTek Corporation, Ashland, MA) were loaded with Fura-2 acetoxymethyl (AM) ester (Thermo Fisher Scientific, Waltham, MA, USA, 5 μM, 15 min, 37 °C). Images were obtained using a dual excitation fluorescence imaging system, as described^[@CR31]^: changes in intracellular Ca^2+^ were expressed as the ratio of fluorescence emission acquired above 510 nm in response to excitation at 340 nm and 380 nm. ER Ca^2+^ was assessed in cells transfected with the luminal Ca^2+^ sensor D1ER (Addgene, Cambridge, MA), as described^[@CR78]--[@CR80]^ and the rate of Ca^2+^ leak was measured as function of \[Ca^2+^\]~ER~ following the addition of thapsigargin (1 μM). To evaluate mitochondrial Ca^2+^, the samples were loaded with rhod-2 AM (Thermo Fisher Scientific, 3 μM, 30 min, 37 °C), followed by washout and 1 hour rest at room temperature for de-esterification^[@CR31],[@CR77],[@CR81]^. Fluorescence was detected using a pass-band filter of 545--625 nm in response to excitation at 542 nm.

Real-time RT-qPCR {#Sec12}
-----------------

Total RNA was isolated from β cells and islets using TRIzol reagent (Thermo Fisher Scientific) in combination with the RNeasy Mini kit (Qiagen, Hilden, Germany) followed by DNase treatment^[@CR82],[@CR83]^, and cDNA was synthesized via a Thermo-Script RT-PCR System (Thermo Fisher Scientific). After reverse transcription, real-time quantitative PCR was performed on an AbiPRISM 7300 fast real-time cycler using the power SYBR Green real-time PCR master mix kit and quantified by built-in SYBR Green Analysis (Thermo Fisher Scientific)^[@CR77],[@CR84]^. Samples were measured in triplicates and results were confirmed by at least three independent experiments. The relative amount of specific mRNA was normalized to Glyceraldehyde 3-phosphate dehydrogenase (*GAPDH*). The sequences of oligonucleotide primers (Merck KGaA, Darmstadt Germany) for gene analysis are listed in Supplementary Table [2](#MOESM1){ref-type="media"}.

Statistical analysis {#Sec13}
--------------------

All results are presented as mean ± s.e.m. Unless otherwise noted, experiments were performed in a blinded fashion at least three times. Statistical analysis was performed via Student's *t* test (for 2 groups) unless otherwise indicated, using Prism 7 software (GraphPad, San Diego, CA, USA). A value of *P* \< 0.05 was considered statistically significant.

Data Availability {#Sec14}
-----------------

All data generated or analyzed during this study are included in the present article.
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